July 15, 2015 - The court granted defendants' motion to dismiss.
April 13, 2015 - The defendants filed a motion to dismiss.

March 2, 2015 - The plaintiff filed another amended complaint.

February 27, 2015 - The plaintiff filed a second amended complaint.

January 28, 2015 - The court granted the defendants motion to dismiss and granted lead plaintiff leave to file an amended complaint.

September 22, 2014 - The defendants filed a motion to dismiss.

August 8, 2014 - The plaintiff filed an amended complaint.

June 24, 2014 - Lead plaintiff and lead counsel were appointed.

April 28, 2014 - Lead plaintiff motions were filed.

February 27, 2014 - An investor in shares of Immunomedics Inc (NASDAQ: IMMU) filed a lawsuit in the U.S. District Court for the District of New Jersey against Immunomedics Inc over alleged violations of Federal Securities Laws in connection with certain allegedly false and misleading statements made between May 9, 2013 and October 9, 2013.

In July 2008, Immunomedics Inc entered into a License and Collaboration Agreement (“Agreement”) with Nycomed GmbH, whereby Immunomedics Inc issued Nycomed GmbH a worldwide license to develop, manufacture and commercialize one of its most advanced therapeutic compounds, Veltuzumab, a humanized monoclonal antibody for the treatment of all non-cancer indications. In September 2011, Nycomed GmbH was acquired by Takeda Pharmaceutical Company “Takeda-Nycomed”.

According to the complaint the plaintiff alleges on behalf of all persons or entities who purchased or otherwise acquired securities of Immunomedics Inc (NASDAQ: IMMU) between May 9, 2013 and October 9, 2013, that Immunomedics Inc and certain of its officers and directors violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.

More specifically, the plaintiff claims that unbeknownst to investors prior to May 9, 2013 and between May 9, 2013 and October 9, 2013 Immunomedics Inc and Takeda-Nycomed were embroiled in an on-going dispute regarding what Immunomedics Inc considered to be an unacceptable delay in the development of Veltuzumab.

On May 14, 2013 Immunomedics Inc provided Takeda-Nycomed with a formal notification that, as a result of the delays in the development in Veltuzumab, it considered Takeda-Nycomed to be in “material breach” of the Agreement and that the Agreement would terminate if the breach remained uncured.

The plaintiff alleges that defendants continued to make positive statements about Veltuzumab and its related development by Takeda-Nycomed.

Shares of Immunomedics Inc (NASDAQ: IMMU) grew from $2.29 per share in March 2013 to $7.141 on October 2, 2013.

However, then on October 9, 2013, Immunomedics Inc announced that the Company has received notification from Takeda Pharmaceutical Company of the termination of the licensing agreement signed between Nycomed GmbH and Immunomedics Inc for the worldwide rights to veltuzumab, the humanized anti-CD20 antibody, for all non-cancer indications.

Shares of Immunomedics Inc declined from over $7 per share in early October 2013 to as low as $3.42 per share in early November 2013.